Session » Rheumatoid Arthritis - Clinical Aspects VI: Remission and Flare in Rheumatoid Arthritis

Meeting: 2012 ACR/ARHP Annual Meeting

Abstract Number: 2605

Exploration of Possible Preliminary Descriptions of Remission Based On RAPID3, without Laboratory Tests or Formal Joints Counts but with Careful Joint Examinations, in the Etude Et Suivi Des Polyarthrites Indifférenciées Récentes (ESPOIR) Cohort of Early Rheumatoid Arthritis Patients

Abstract Number: 2606

Patient Reported Outcomes in Early Arthritis Patients

Abstract Number: 2607

Adherence to a Treat-to-Target Strategy in Early Rheumatoid Arthritis: Results of the Dutch Rheumatoid Arthritis Monitoring Remission Induction Cohort

Abstract Number: 2608

Time in Remission Is Important for Improvement of Physical Function in Patients with Rheumatoid Arthritis (RA)

Abstract Number: 2609

Construct and Criterion Validity of Several Proposed DAS28 Based Rheumatoid Arthritis Flare Criteria: A Cohort Validation Study

Abstract Number: 2610

Predictors of Sustained Clinical Remissionin Early Rheumatoid Arthritis – Results From the Canadian Early Arthritis Cohort

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.